Cardiac implantable electronic device trends and infection risk in cardiac sarcoidosis: A 30-year perspective from southern and western Sweden
Authors' conclusion
In CS, early recognition and ICD utilization, particularly for primary prevention, have increased. CIED infection rates were similar regardless of the timing of immunosuppression initiation relative to CIED implantation.
Study context
- Population
- Patients with cardiac sarcoidosis who received a CIED, 1994–2023received a CIED, of 212 patients diagnosed with cardiac sarcoidosis (CS)
- Participants
- 140 patients
- Exposure
- Device type and indications before and after the 2014 Heart Rhythm Society consensus (1994-2014 vs 2015-2023); CIED infection rates according to immunosuppression initiation (>10 days after implantation vs within or before 10 days)
- Outcome
- ICD as first implanted device
Methodological details2 Swedish tertiary centers
- 2 Swedish tertiary centers
Main finding
As reported in the abstract
- Implantable cardioverter-defibrillator (ICDs) first implanted device, overall
- 70.7%
- For primary prevention
- 59.7%
Observational data: associations, not effects.
Further findings
| Outcome | Mean interval (years) | P value |
|---|---|---|
| Mean interval from CS diagnosis to CIED implantationAfter 2014 vs before 2014 · significantly shortened after 2014 | −1.5 vs 0.1 years | P = 0.037 |
Safety
| Outcome | 1994-2014 | 2015-2023 | Delayed immunosuppression | Early-initiated immunosuppression | |
|---|---|---|---|---|---|
| CIED infection · 1 year | Not reported in the abstract | Not reported in the abstract | 7.5% | 5% | 1994-2014, 2015-2023: not reported in the abstract |
- CIED infection — overall CIED infection rate
- 6.4% (n = 9)
Original publication
Cardiac implantable electronic device trends and infection risk in cardiac sarcoidosis: A 30-year perspective from southern and western Sweden. Heart Rhythm. Published 6 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it